🍽️ mesalamine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Anti-inflammatory Action: Mesalamine belongs to a class of medications known as aminosalicylates, which have potent anti-inflammatory properties. It works by inhibiting the production of inflammatory chemicals in the intestines, thereby reducing inflammation and alleviating symptoms associated with ulcerative colitis and Crohn's disease.

  2. Induction and Maintenance of Remission: Mesalamine is effective in inducing and maintaining remission in patients with mild to moderate ulcerative colitis and Crohn's disease. It helps control symptoms such as diarrhea, abdominal pain, rectal bleeding, and urgency by reducing intestinal inflammation and promoting mucosal healing.

  3. Topical and Systemic Formulations: Mesalamine is available in various formulations, including oral tablets, capsules, extended-release tablets, and rectal suppositories or enemas. The choice of formulation depends on the location and severity of the inflammation within the gastrointestinal tract. Topical formulations are often preferred for treating inflammation in the rectum and distal colon, while systemic formulations are used for more extensive disease involvement.

  4. Site-Specific Action: Mesalamine exerts its therapeutic effects locally within the gastrointestinal tract, targeting inflamed areas directly. By delivering the medication to the site of inflammation, mesalamine minimizes systemic exposure and reduces the risk of systemic side effects compared to corticosteroids and immunosuppressive agents.

  5. Reduction of Symptomatic Flares: Mesalamine therapy helps reduce the frequency and severity of symptomatic flares in patients with ulcerative colitis and Crohn's disease, thereby improving quality of life and reducing the need for corticosteroids or hospitalization. It is often used as a first-line treatment option in mild to moderate disease or as adjunctive therapy in combination with other medications in more severe cases.

  6. Safety Profile: Mesalamine is generally well-tolerated, with the most common adverse effects being mild and transient gastrointestinal symptoms such as nausea, diarrhea, abdominal cramps, and flatulence. Serious side effects such as allergic reactions, pancreatitis, liver dysfunction, and kidney problems are rare but may occur, particularly with long-term use or high doses.

  7. Monitoring: Patients receiving mesalamine therapy require regular monitoring of symptoms, disease activity, and potential side effects. Healthcare providers may perform periodic assessments, including physical examinations, laboratory tests (e.g., complete blood count, liver function tests, renal function tests), and imaging studies (e.g., colonoscopy) to evaluate treatment response and monitor for complications.

  8. Dose Adjustment: The dosage of mesalamine may need to be adjusted based on disease severity, response to treatment, and individual patient factors. Healthcare providers may prescribe different dosing regimens, ranging from once-daily to multiple-times-daily administration, to optimize therapeutic efficacy while minimizing side effects.

  9. Pregnancy and Lactation: Mesalamine is considered relatively safe for use during pregnancy and breastfeeding, although the decision to use the medication should be made in consultation with a healthcare provider. The benefits of mesalamine therapy in controlling inflammatory bowel disease should be weighed against the potential risks to the mother and fetus.

  10. Long-Term Maintenance Therapy: Mesalamine is often prescribed as a long-term maintenance therapy to prevent disease recurrence and maintain remission in patients with ulcerative colitis and Crohn's disease. Compliance with treatment is essential to achieve optimal outcomes and minimize the risk of disease progression or complications.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of mesalamine,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by mesalamine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Lacrimispora genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Lacticaseibacillus genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of mesalamine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.2 0.1 1
Age-Related Macular Degeneration and Glaucoma 0.2 0.1 1
Allergic Rhinitis (Hay Fever) 0.1 0.1
Allergies 0 0
Allergy to milk products 0.1 -0.1
Alopecia (Hair Loss) 0.2 0.2
Alzheimer's disease 0.1 0.3 -2
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.1 0.1
Ankylosing spondylitis 0.2 0.2
Anorexia Nervosa 0.1 0.2 -1
Antiphospholipid syndrome (APS) 0.3 0.3
Asthma 0 0.2 0
Atherosclerosis 0.5 -0.5
Atrial fibrillation 0.2 0.1 1
Autism 0.4 0.4 0
Barrett esophagus cancer 0 0
Biofilm 0 0
Bipolar Disorder 0.1 0.3 -2
Brain Trauma 0.2 -0.2
Cancer (General) 0.1 -0.1
Carcinoma 0.1 0.1 0
Celiac Disease 0 0.1 0
Cerebral Palsy 0 0.2 0
Chronic Fatigue Syndrome 0.2 0.5 -1.5
Chronic Kidney Disease 0.1 0.3 -2
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.3 -2
Chronic Urticaria (Hives) 0 0
Coagulation / Micro clot triggering bacteria 0.1 0.2 -1
Colorectal Cancer 0.2 0.2
Constipation 0.2 -0.2
Coronary artery disease 0.1 -0.1
COVID-19 0.1 0.6 -5
Crohn's Disease 0.3 0.3 0
cystic fibrosis 0.2 -0.2
deep vein thrombosis 0.2 -0.2
Depression 0.9 0.6 0.5
Dermatomyositis 0 0
Eczema 0 0
Endometriosis 0.2 0.2
Epilepsy 0 0.1 0
Fibromyalgia 0.2 0.2 0
Functional constipation / chronic idiopathic constipation 0.4 0.3 0.33
gallstone disease (gsd) 0.1 0.2 -1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0 0
Generalized anxiety disorder 0.1 -0.1
Glioblastoma 0 0
Gout 0.1 -0.1
Graves' disease 0.1 0.2 -1
Halitosis 0 0
Hashimoto's thyroiditis 0.2 0.2
Hidradenitis Suppurativa 0 0
High Histamine/low DAO 0.2 0.2
hyperglycemia 0.1 -0.1
hypertension (High Blood Pressure 0.1 0.3 -2
Hypothyroidism 0.1 -0.1
Hypoxia 0.1 0.1
Inflammatory Bowel Disease 0 0.7 0
Insomnia 0 0.2 0
Intelligence 0.1 0.1
Intracranial aneurysms 0.1 0.1
Irritable Bowel Syndrome 0.2 0.2 0
Liver Cirrhosis 0.4 0.3 0.33
Long COVID 0.3 0.3 0
Low bone mineral density 0.3 -0.3
Mast Cell Issues / mastitis 0 0.1 0
ME/CFS with IBS 0 0.2 0
ME/CFS without IBS 0.2 0.2 0
Metabolic Syndrome 0.4 0.4 0
Mood Disorders 1 0.6 0.67
multiple chemical sensitivity [MCS] 0 0
Multiple Sclerosis 0.2 0.4 -1
Multiple system atrophy (MSA) 0 0
Neuropathy (all types) 0 0
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0 0.1 0
Obesity 0.4 0.3 0.33
obsessive-compulsive disorder 0.1 0.1 0
Osteoarthritis 0 0
Osteoporosis 0 0
pancreatic cancer 0 0
Parkinson's Disease 0.2 0.6 -2
Polycystic ovary syndrome 0.1 0.2 -1
Postural orthostatic tachycardia syndrome 0.1 -0.1
Premenstrual dysphoric disorder 0.1 -0.1
Psoriasis 0 0.5 0
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.4 0.3 0.33
Rosacea 0.2 -0.2
Schizophrenia 0.2 0.3 -0.5
scoliosis 0.1 0.1
Sjögren syndrome 0.1 0.1 0
Sleep Apnea 0.1 0.3 -2
Small Intestinal Bacterial Overgrowth (SIBO) 0 0
Stress / posttraumatic stress disorder 0.2 0.3 -0.5
Systemic Lupus Erythematosus 0.2 0.2 0
Type 1 Diabetes 0.1 0.2 -1
Type 2 Diabetes 0.4 0.4 0
Ulcerative colitis 0.1 0.3 -2
Unhealthy Ageing 0.1 0.3 -2

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]